<?xml version='1.0' encoding='UTF-8'?><xml><records><record><source-app name="HighWire" version="7.x">Drupal-HighWire</source-app><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Alexander, Lori</style></author></authors><secondary-authors><author><style face="normal" font="default" size="100%">Scirica, Benjamin M.</style></author></secondary-authors></contributors><titles><title><style face="normal" font="default" size="100%">Study Supports Anti-Arrhythmic Effects of Ranolazine in Patients with Acute Coronary Syndrome</style></title><secondary-title><style face="normal" font="default" size="100%">MD Conference Express</style></secondary-title></titles><dates><year><style  face="normal" font="default" size="100%">2007</style></year><pub-dates><date><style  face="normal" font="default" size="100%">2007-10-01 00:00:00</style></date></pub-dates></dates><pages><style  face="normal" font="default" size="100%">13-14</style></pages><abstract><style  face="normal" font="default" size="100%">Ranolazine, an anti-ischemic agent approved for use in the treatment of chronic angina, has also been shown to have anti-arrhythmic effects in experimental models. The MERLIN-TIMI 36 trial was the first study in which the anti-arrhythmic effects of ranolazine were evaluated in humans.</style></abstract><number><style face="normal" font="default" size="100%">5</style></number><volume><style face="normal" font="default" size="100%">7</style></volume></record></records></xml>